Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Martin, Tom; Richardson, Paul G.; Façon, Thierry; Moreau, Philippe; Perrot, Aurore; Špıčka, Ivan; Bisht, Kamlesh; Inchauspé, Marlène; Casca, France; Macé, Sandrine; Velde, Helgi van de; Suzuki, Kenshi

doi:10.3324/haematol.2022.280660

Cited by 16 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…128 A larger percentage of patients with isolated 1q21+ achieved MRD− with Isa-Kd (36.2%) versus Kd alone (9.7%); these were similar to the proportions in standard-risk patients (36.9% vs. 14.0%). 128 A retrospective analysis of RRMM patients with 1q21+ treated with daratumumab-based regimens (monotherapy, Dara-Rd, Dara-Pd, or Dara-Vd) was recently presented. 129 In this analysis, 57 of 278 patients (20%) had 1q21+, and gain1q21 was present in a majority of patients; only 4 patients had amp1q21.…”

Section: Newly Diagnosed MMmentioning

confidence: 56%

“…128 In IKEMA, mPFS in patients with 1q21+ was not reached and 16.2 months, respectively, in the Isa-Kd and Kd arms (HR = 0.57; 95% CI: 0.33-0.98). 128 A larger percentage of patients with isolated 1q21+ achieved MRD− with Isa-Kd (36.2%) versus Kd alone (9.7%); these were similar to the proportions in standard-risk patients (36.9% vs. 14.0%). 128 A retrospective analysis of RRMM patients with 1q21+ treated with daratumumab-based regimens (monotherapy, Dara-Rd, Dara-Pd, or Dara-Vd) was recently presented.…”

Section: Newly Diagnosed MMmentioning

confidence: 89%

“…In RRMM, subgroup analyses of patients with 1q21+ have been reported for the ICARIA‐MM and IKEMA studies investigating isatuximab 128 . In ICARIA‐MM, the mPFS in patients with 1q21+ was 9.5 months versus 3.8 months in the Isa‐Pd versus Pd arms, respectively (HR = 0.40; 95% CI: 0.25–0.63) 128 .…”

Section: Therapeutic Applications Of Anti‐cd38 Targeting Antibodiesmentioning

confidence: 99%

“…127 Some recent reports have analyzed outcomes in patients with 1q21+ receiving different anti-CD38 therapies, with the results showing possible differences in outcomes among the different regimens evaluated. [128][129][130] In the MAIA trial investigating daratumumab plus lenalidomide and dexamethasone (Dara-Rd) in transplant-ineligible NDMM patients, subgroup analysis of PFS in patients with 1q21+ and more than 1 other high-risk chromosomal abnormality showed an HR of 1.03 (95% CI: 0.42-2.48). 131 A subgroup analysis of the GRIFFIN trial investigating daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (Dara-RVd) in transplant-eligible NDMM patients T A B L E 1 Summary of available Phase 3 clinical trial efficacy results for anti-CD38 treatments in MM.…”

Section: Clinical Trial Findings For Cd38 Antibodies In Patients With MMmentioning

confidence: 99%

“…Hyperdiploid patients with 1q+ also showed significant depletion of B‐cell lineage cell types 127 . Some recent reports have analyzed outcomes in patients with 1q21+ receiving different anti‐CD38 therapies, with the results showing possible differences in outcomes among the different regimens evaluated 128–130 . In the MAIA trial investigating daratumumab plus lenalidomide and dexamethasone (Dara‐Rd) in transplant‐ineligible NDMM patients, subgroup analysis of PFS in patients with 1q21+ and more than 1 other high‐risk chromosomal abnormality showed an HR of 1.03 (95% CI: 0.42–2.48) 131 .…”

Section: Therapeutic Applications Of Anti‐cd38 Targeting Antibodiesmentioning

confidence: 99%

See 4 more Smart Citations

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Bisht,

Fukao,

Chiron

et al. 2023

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

BackgroundCD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and other metabolites.AimAmong the various mechanisms by which CD38 antibodies can induce MM cell death is immunomodulation, including multiple pathways for CD38‐mediated T‐cell activation. Patients who respond to anti‐CD38 targeting treatment experience more marked changes in T‐cell expansion, activity, and clonality than nonresponders.ImplicationsResistance mechanisms that undermine the immunomodulatory effects of CD38‐targeting therapies can be tumor intrinsic, such as the downregulation of CD38 surface expression and expression of complement inhibitor proteins, and immune microenvironment‐related, such as changes to the natural killer (NK) cell numbers and function in the bone marrow niche. There are numerous strategies to overcome this resistance, which include identifying and targeting other therapeutic targets involved in, for example, adenosine production, the activation of NK cells or monocytes through immunomodulatory drugs and their combination with elotuzumab, or with bispecific T‐cell engagers.

show abstract

Section: Newly Diagnosed MMmentioning

confidence: 56%

Section: Newly Diagnosed MMmentioning

confidence: 89%

Section: Therapeutic Applications Of Anti‐cd38 Targeting Antibodiesmentioning

confidence: 99%

Section: Clinical Trial Findings For Cd38 Antibodies In Patients With MMmentioning

confidence: 99%

Section: Therapeutic Applications Of Anti‐cd38 Targeting Antibodiesmentioning

confidence: 99%

See 3 more Smart Citations

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Bisht,

Fukao,

Chiron

et al. 2023

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China

Xiong,

Liang,

Tang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundChromosomal 1q gains and amplifications (+1q21) are frequently observed in patients with newly diagnosed multiple myeloma (NDMM). However, the interpretation of the high‐risk (HR) prognostic implications stemming from 1q21 abnormalities remain challenging to implement effectively.MethodsIn a comprehensive analysis of 367 consecutive patients with symptomatic MM, we assessed the prognostic significance of +1q21 using FISH with a threshold of 7.4%. The patient cohort was randomly divided into a training set (66.5%, n = 244) and a validation set (33.5%, n = 133). A multivariate Cox regression analysis was conducted to identify significant prognostic factors associated with PFS. Weight scores were assigned to each risk factor based on the β‐value of the corresponding regression coefficient. A predictive risk‐scoring model involving +1q21 was then developed, utilizing the total score derived from these weight scores. The model's discriminative ability was evaluated using the AUC in both the training and validation sets. Finally, we compared the performance of the +1q21‐involved risk with the established R‐ISS and R2‐ISS models.ResultsUpon initial diagnosis, 159 patients (43.32%) exhibited +1q21, with 94 (59.11%) having three copies, referred to as Gain(1q21), and 65 (40.89%) possessing four or more copies, referred to as Amp (1q21). Both were significantly linked to a reduced PFS in myeloma (p < 0.05), which could be effectively mitigated by ASCT. The +1q21‐involved risk model, with an AUC of 0.697 in the training set and 0.725 in the validation set, was constructed including Gain(1q21), Amp(1q21), no‐ASCT, and TP53 deletion. This model, termed the ultra‐high‐risk (UHR) model, demonstrated superior performance in predicting shorter PFS compared to the R‐ISS stage 3 and R2‐ISS stage 4.ConclusionThe UHR model, which integrates the presence of +1q21 with no‐ASCT and TP53 deletion, is designed to identify the early relapse subgroup among patients with +1q21 in NDMM.

show abstract

Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study

Facon,

Moreau,

Špicka

et al. 2024

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

Gain/amplification of 1q21 (≥3 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti‐myeloma therapy and disease progression. In this updated subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285) in relapsed/refractory multiple myeloma (RRMM), we evaluated progression‐free survival (PFS) and depth of response with the anti‐CD38 antibody isatuximab plus carfilzomib‐dexamethasone (Isa‐Kd) versus Kd, in 1q21+ patients and related subgroups, at long‐term follow‐up (44.2 months). Our analysis included patients with 1q21+ (≥3 copies, with/without high‐risk chromosomal abnormality [HRCA]), isolated 1q21+ (≥3 copies, without HRCA), gain(1q21) (3 copies, with/without HRCA), and amp(1q21) (≥4 copies, with/without HRCA). PFS benefit was achieved with Isa‐Kd versus Kd in patients with 1q21+ (HR 0.58, 95% CI: 0.37–0.92), with isolated 1q21+ (HR 0.49, 95% CI: 0.27–0.92), with gain(1q21), or amp(1q21), consistent with the overall population and prior interim 1q21+ subgroup analyses. Median PFS with Isa‐Kd versus Kd was 25.8 versus 16.2 months in 1q21+ patients and 38.2 versus 16.2 months in patients with isolated 1q21+. Clinically meaningful, higher rates of very good partial response or better, complete response or better (≥CR), minimal residual disease (MRD) negativity, and MRD negativity and ≥CR were reached with Isa‐Kd versus Kd in patients with 1q21+, isolated 1q21+, gain(1q21), or amp(1q21). In Isa‐Kd and Kd, the MRD negativity and ≥CR rate was 29.3% versus 15.4% in 1q21+ patients, 36.2% versus 12.9% in patients with isolated 1q21+, 27.9% versus 13.5% in patients with gain(1q21), and 31.3% versus 20.0% in patients with amp(1q21), respectively. In conclusion, addition of Isa to Kd in triplet combination therapy has shown PFS benefit and deeper responses, compared with Kd, in 1q21+ patients at higher risk of progression, including patients with isolated 1q21+, gain(1q21), and amp(1q21), thus supporting Isa‐Kd an effective treatment option for patients with RRMM.

show abstract

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

Abstract: Not available.

Cited by 16 publications

References 17 publications

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China

Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study

Contact Info

Product

Resources

About